Vaxart's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 25.03.
Vaxart's Days Inventory for the
three
months ended in Mar. 2026 was 0.
Vaxart's Days Payable for the
three
months ended in Mar. 2026 was 0.
Therefore, Vaxart's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 25.03.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Vaxart Cash Conversion Cycle Related Terms
Vaxart Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Vaxart's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:NB11 vs SPRO, ADCT, GNLX: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Vaxart's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxart Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxart's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Vaxart's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Vaxart's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxart (STU:NB11) has a Cash Conversion Cycle of 25.03 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vaxart and its competitors.
Is Vaxart's Cash Conversion Cycle too high?
Vaxart's current Cash Conversion Cycle is 25.03. The Biotechnology industry median Cash Conversion Cycle is 103.21. Vaxart's value of 25.03 is 75.7% below this industry median. Overall, Vaxart has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Vaxart's Cash Conversion Cycle compare to SPRO and ADCT?
Vaxart's Cash Conversion Cycle of 25.03 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.21. Vaxart's value of 25.03 is 75.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.21, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxart's current Cash Conversion Cycle of 25.03 is 75.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Vaxart and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxart's current Cash Conversion Cycle is 25.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxart stock overvalued right now?
Vaxart (STU:NB11) has a current Cash Conversion Cycle of 25.03. The stock's GF Value™ is €8.82, compared to a current price of €0.60 — trading 93.2% below its estimated fair value. The current Cash Conversion Cycle is 25.03 and 75.7% below the Biotechnology industry median of 103.21. Vaxart's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Vaxart (STU:NB11), the current Cash Conversion Cycle is 25.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaxart (STU:NB11) Overvalued in 2026?
Based on GuruFocus' analysis, Vaxart stock appears to be undervalued.
The current stock price of €0.60 is trading 93.2% below its estimated GF Value™ of €8.82.
Key valuation signals for STU:NB11:
Cash Conversion Cycle: 25.03
GF Value™: €8.82 vs. price of €0.60 (93.2% below fair value)
Industry Position: 75.7% below the Biotechnology median
No single metric tells the full story. See the STU:NB11 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
63GF Score
Get the complete analysis for STU:NB11
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NB11 has been successfully added to your 
